

Appln. No. 10/825,472  
Response to Office Action of August 21, 2006

Docket No. 98204.00024

RECEIVED  
CENTRAL FAX CENTER

OCT 17 2006

**AMENDMENT TO THE CLAIMS**

Claims 1-24 are currently pending and stand restricted. Applicant elects Group I, claims 1-17, drawn to a pharmaceutical agent for prosecution on the merits. By the current amendment Applicant has withdrawn claims 18-24 directed to methods of treating a disease. However, Applicant notes that method claims may be rejoined should the product claims be found allowable. Applicant requests that the amended claims be entered and that the Examiner proceed with substantive examination. Applicant believes that the claims are now in condition for allowance, and notification to that effect is respectfully requested. The following amendments contain no new matter. This listing replaces all prior versions, and listings of claims in the application.

**In The Claims:**

1. (Original) A pharmaceutical agent having the formula

Carrier — Linker — Peptide

wherein Peptide is a peptide having the formula  $aa_n$ , where  $n$  is an integer  $\leq 40$ , Carrier is a member selected from the group consisting of cinnamoyl, benzoyl, phenylacetyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-dimethoxycinnamoyl, 3,4,5-trimethoxy-cinnamoyl, *t*-butoxy-carbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylthoxycarbonyl, fumaroyl and derivatives thereof and Linker is a member selected from the group consisting of C6 to C16 lipidic chains and derivatives thereof, 8-amino-3,6-dioxaoctanoic acid and polymeric derivatives thereof, natural peptides, pseudopeptides of less than 4 residues, peptide mimics of less than 4 residues and combinations thereof.

2. (Original) The pharmaceutical agent of claim 1 wherein Linker is a member selected from the group consisting of natural peptides, pseudo peptides of less than 4 residues and peptide mimics of less than 4 residues.
3. (Original) The pharmaceutical agent of claim 1, wherein  $n$  is an integer of from 3 to 6.
4. (Original) The pharmaceutical agent of claim 1, wherein  $n$  is 5.

Appln. No. 10/825,472

Docket No. 98204.00024

Response to Office Action of August 21, 2006

5. (Original) The pharmaceutical agent of claim 1, wherein Peptide is Tyr-Gly-Gly-Phe-Met.
6. (Original) The pharmaceutical agent of claim 1 wherein Carrier is a member selected from the group consisting of cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3-methoxycinnamoyl, 3,4-dimethoxycinnamoyl, and 3,4,5-trimethoxy-cinnamoyl.
7. (Original) The pharmaceutical agent of claim 1 wherein Carrier is cinnamoyl.
8. (Original) The pharmaceutical agent of claim 1 wherein Linker is a -C6 or C8 acidic moiety.
9. (Original) The pharmaceutical agent of claim 1 wherein Linker is  $G\psi(CH_2-CH_2)G$ .
10. (Original) The pharmaceutical agent of claim 1 wherein Peptide is an epitope or an immune sequence characteristic of an infectious, viral or cancerous disease.
11. (Original) A pharmaceutical composition for administration to a patient in need thereof comprising a pharmaceutical agent according to claim 1 and one or more pharmaceutically acceptable adjuvants.
12. (Original) The pharmaceutical composition of claim 11 wherein the composition is formulated for oral administration.
13. (Original) The pharmaceutical composition of claim 11 wherein the composition is formulated for parenteral administration.
14. (Original) The pharmaceutical composition of claim 11 wherein the composition is formulated for intravenous administration.
15. (Original) The pharmaceutical composition of claim 11 wherein the composition releases a biologically active form of the pharmaceutical agent into the patent's system at physiologically effective levels over a period of time of up to twelve hours.

Appln. No. 10/825,472

Docket No. 98204.00024

Response to Office Action of August 21, 2006

16. (Original) The pharmaceutical composition of claim 11 wherein the composition releases a biologically active form of the pharmaceutical agent into the patient's system at physiologically effective levels over a period of time of up to twenty-four hours.
17. (Original) The pharmaceutical composition according to claim 11 wherein Peptide is an epitope or an immune sequence characteristic of an infectious, viral or cancerous disease.
18. (Withdrawn) A method for treatment of a physiological condition through administration of a peptide species comprising the steps of chemically linking a peptide of the general formula  $aa_n$ , where  $aa$  is an amino acid, and where  $n$  is an integer  $\leq 40$ , to an alkyl or aryl carrier moiety to form a pro-drug, and administering the pro-drug to a patient exhibiting the physiological condition.
19. (Withdrawn) The method of claim 18 wherein the peptide is poorly absorbed orally.
20. (Withdrawn) A method for the treatment of a physiological condition which comprises administering a pharmaceutical agent according to claim 1 to a patient exhibiting the physiological condition.
21. (Withdrawn) The method according to claim 20 wherein the pharmaceutical agent is administered orally or parenterally.
22. (Withdrawn) A method for the treatment of a physiological condition which comprises administering a pharmaceutical agent having the formula Carrier — Linker<sub>x</sub> — Peptide wherein  $X$  is 0 or 1, Peptide is a peptide having the formula  $aa_n$ , wherein  $n$  is an integer  $\leq 40$ , Carrier is a member selected from the group consisting of cinnamoyl, benzoyl, phenylacetyl, 3-OH-cinnamoyl, 3,4-methylene-dioxycinnamoyl, 3-methoxycinnamoyl, 3,4-dimethoxycinnamoyl, 3,4,5-trimethoxy-cinnamoyl, *t*-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a member selected from the group consisting of C6 to C16 lipidic chains and derivatives thereof, 8-amino-3,6-dioxaoctanoic acid and polymeric derivatives thereof, natural peptides, pseudopeptides of less than 4 residues, peptide mimics of less than 4 residues and combinations thereof.

Appl. No. 10/825,472

Docket No. 98204.00024

Response to Office Action of August 21, 2006

23. (Withdrawn) The method for the treatment of a physiological condition according to claim 22 which comprises administering a pharmaceutical agent wherein x is 0 and Carrier — Peptide is a pro-drug.

24. (Withdrawn) The method for the treatment of a physiological condition according to claim 22 which comprises administering a pharmaceutical composition wherein x is 1 and Carrier — Linker — Peptide is a pro-drug.